TNFRSF17 and classic Hodgkin lymphoma: These results suggest that these proteins may help pathologists in complex diagnoses and reinforce the interest in developing clinical trials assessing Netrin‐1 or BCMA‐targeted therapies in plasmablastic lymphoma and classical Hodgkin lymphomas, for which our therapeutic arsenal is weak.